{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:30:56Z","timestamp":1790771456349,"version":"4.1.0"},"reference-count":28,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Purpose: To present data on clinical response to eplerenone over a 1-year period in patients with central serous chorioretinopathy (CSC), and to evaluate optical coherence tomography (OCT) variables as predictors of treatment response at 3- and 12-month follow-up visits. Methods: Patients with acute or chronic CSC treated with eplerenone were retrospectively included. Clinical and imaging characteristics were recorded at baseline and at the 3-month and 12-month follow-up visits. Changes from baseline in quantitative measurements were calculated at each follow-up. Logistic regression analysis was computed to correlate clinical and OCT parameters at baseline with response to treatment at 3 and 12 months of follow-up. Results: A total of 50 eyes of 50 patients were included in the study. Mean \u00b1 SD best corrected visual acuity (BCVA) was 0.20 \u00b1 0.14 Logarithm of the Minimum Angle of Resolution (LogMAR) at baseline and significantly improved at both the 3-month (0.12 \u00b1 0.13 LogMAR, p &lt; 0.0001) and 12-month (0.10 \u00b1 0.12 LogMAR, p &lt; 0.0001) follow-up visits. At the 3-month follow-up visit, 25 out of 50 eyes (50.0%) demonstrated macular complete subretinal fluid (SRF) resolution, while 13 eyes (26.0%) showed macular partial SRF resolution, and 12 eyes (24%) had neither partial nor complete macular SRF resolution. Among those patients with macular partial or complete SRF resolution at 3 months and thus not shifted to photodynamic therapy, 36 out of 38 cases had macular complete SRF resolution at the 12-month follow-up visit. There was a significant change from baseline at both follow-up visits in all anatomical OCT parameters (except for reduction in choroidal thickness that did not reach the statistical significance at the 12-month follow-up visit). Several OCT parameters at baseline were independently significant predictors for macular subretinal fluid complete resolution at 3 months, including (i) a thicker subfoveal choroidal thickness; (ii) a smaller subretinal fluid maximum diameter; (iii) a lower number of serous pigment epithelium detachments; and (iv) a lower number of intraretinal hyperreflective foci. Conclusion: Treatment with eplerenone in CSC patients is confirmed to be beneficial for both anatomical and functional outcomes. We identified attractive OCT metrics that could potentially be used as a tool to select patients who might mainly benefit from this treatment.<\/jats:p>","DOI":"10.3390\/jcm8091271","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T10:15:07Z","timestamp":1566555307000},"page":"1271","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Optical Coherence Tomography Parameters as Predictors of Treatment Response to Eplerenone in Central Serous Chorioretinopathy"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-5031","authenticated-orcid":false,"given":"Enrico","family":"Borrelli","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan 20132, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biancamaria","family":"Zuccaro","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan 20132, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Zucchiatti","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan 20132, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Parravano","sequence":"additional","affiliation":[{"name":"IRCCS-Fondazione Bietti, Rome 00198, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Querques","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan 20132, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Costanzo","sequence":"additional","affiliation":[{"name":"IRCCS-Fondazione Bietti, Rome 00198, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Sacconi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan 20132, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Prascina","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan 20132, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5444-4377","authenticated-orcid":false,"given":"Fabio","family":"Scarinci","sequence":"additional","affiliation":[{"name":"IRCCS-Fondazione Bietti, Rome 00198, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan 20132, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-9581","authenticated-orcid":false,"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan 20132, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","article-title":"The Incidence of Central Serous Chorioretinopathy in Olmsted County, Minnesota, 1980\u20132002","volume":"115","author":"Kitzmann","year":"2008","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1442-9071.2012.02847.x","article-title":"Diagnosis and interventions for central serous chorioretinopathy: Review and update","volume":"41","author":"Quin","year":"2013","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006982-200202000-00004","article-title":"Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy","volume":"22","author":"Loo","year":"2002","journal-title":"Retina"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1172\/JCI61427","article-title":"Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy","volume":"122","author":"Zhao","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/jamaophthalmol.2017.0245","article-title":"Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, with Chronic Central Serous Chorioretinopathy","volume":"135","author":"Schellevis","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1111\/aos.13491","article-title":"Eplerenone for chronic central serous chorioretinopathy\u2014A randomized controlled prospective study","volume":"95","author":"Schwartz","year":"2017","journal-title":"Acta Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","article-title":"Spironolactone for nonresolving central serous chorioretinopathy a randomized controlled crossover study","volume":"35","author":"Bousquet","year":"2015","journal-title":"Retina"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40123-018-0121-2","article-title":"Eplerenone Versus Observation in the Treatment of Acute Central Serous Chorioretinopathy: A Retrospective Controlled Study","volume":"7","author":"Zucchiatti","year":"2018","journal-title":"Ophthalmol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1111\/aos.12392","article-title":"The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy","volume":"92","author":"Breukink","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/17469899.2017.1259565","article-title":"Mineralocorticoid receptor antagonists in the treatment of central serous chorioretinopathy","volume":"12","author":"Montorio","year":"2017","journal-title":"Expert Rev. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/IAE.0000000000000748","article-title":"Central Serous Chorioretinopathy Treated With Mineralocorticoid Antagonists: A One-Year Pilot Study","volume":"36","author":"Ghadiali","year":"2015","journal-title":"Retina"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/bjophthalmol-2018-312892","article-title":"Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy","volume":"103","author":"Zola","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Van Rijssen, T.J., Van Dijk, E.H., Yzer, S., Ohno-Matsui, K., Keunen, J.E., Schlingemann, R.O., Sivaprasad, S., Querques, G., Downes, S.M., and Fauser, S. (2019). Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog. Retin. Eye Res.","DOI":"10.1016\/j.preteyeres.2019.07.003"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/eye.2017.295","article-title":"Response of central serous chorioretinopathy evaluated by multimodal retinal imaging","volume":"32","author":"Sacconi","year":"2018","journal-title":"Eye"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2018.09.034","article-title":"Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy","volume":"198","author":"Bousquet","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1167\/iovs.11-8755","article-title":"Signal Quality Assessment of Retinal Optical Coherence Tomography Images","volume":"53","author":"Huang","year":"2012","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1097\/IAE.0000000000000929","article-title":"Baseline spectral domain optical coherence tomographic hyperreflective foci as a predictor of visual outcome and recurrence for central serous chorioretinopathy","volume":"36","author":"Lee","year":"2016","journal-title":"Retina"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Petkovsek, D.S., Cherfan, D.G., Conti, F.F., Hom, G.L., Ehlers, J.P., Babiuch, A.S., Rachitskaya, A.V., Kaiser, P.K., Schachat, A.P., and Srivastava, S.K. (2019). Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. Br. J. Ophthalmol.","DOI":"10.1136\/bjophthalmol-2019-314047"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1167\/iovs.12-10895","article-title":"Repeatability of Spectralis OCT Measurements of Macular Thickness and Volume in Diabetic Macular Edema","volume":"53","author":"Comyn","year":"2012","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Toto, L., D\u2019Aloisio, R., Mastropasqua, R., Di Antonio, L., Di Nicola, M., Di Martino, G., Evangelista, F., Erroi, E., Doronzo, E., and Mariotti, C. (2019). Anatomical and Functional Changes of the Retina and the Choroid after Resolved Chronic CSCR. J. Clin. Med., 8.","DOI":"10.3390\/jcm8040474"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1442-9071.2006.01447.x","article-title":"Alterations of retinal pigment epithelium in central serous chorioretinopathy","volume":"35","author":"Hirami","year":"2007","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00417-019-04333-y","article-title":"Patient characteristics of untreated chronic central serous chorioretinopathy patients with focal versus diffuse leakage","volume":"257","author":"Scholz","year":"2019","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00417-016-3436-5","article-title":"Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR)","volume":"255","author":"Herold","year":"2017","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/IAE.0000000000001303","article-title":"Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy","volume":"37","author":"Gergely","year":"2017","journal-title":"Retina"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1167\/iovs.18-24143","article-title":"Quantity of Intraretinal Hyperreflective Foci in Patients With Intermediate Age-Related Macular Degeneration Correlates with 1-Year Progression","volume":"59","author":"Nassisi","year":"2018","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/sj.eye.6702073","article-title":"Assessment of the reproducibility and repeatability of a method of grading macular subretinal fluid using optical coherence tomography","volume":"26","author":"Benson","year":"2006","journal-title":"Eye"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1167\/iovs.10-6811","article-title":"Reproducibility of Retinal and Choroidal Thickness Measurements in Enhanced Depth Imaging and High-Penetration Optical Coherence Tomography","volume":"52","author":"Ikuno","year":"2011","journal-title":"Investig. Opthalmol. Vis. Sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/9\/1271\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:12:58Z","timestamp":1760188378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/9\/1271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["jcm8091271"],"URL":"https:\/\/doi.org\/10.3390\/jcm8091271","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,22]]}}}